Health Catalyst, Inc. filings document operating results, material-event reporting, and governance changes for a Nasdaq-listed healthcare data and analytics company. Recent Form 8-K disclosures include quarterly and annual financial results, preliminary unaudited financial updates, and press-release exhibits furnished under results-of-operations items.
The company’s filings also cover board appointments, executive transitions, compensatory arrangements, transition and separation agreements, executive severance-plan references, workforce-reduction disclosures, and related governance matters. These records provide formal disclosure around Health Catalyst’s management structure, financial condition, and material corporate events.
Health Catalyst insider sale notice. A Form 144 filing dated 02/26/2026 indicates a proposed sale of 6,614 shares of common stock (restricted stock) of Health Catalyst, Inc. through Morgan Stanley Smith Barney LLC. The filing also discloses prior sales of 16,401 shares on 12/01/2025 for $47,566.18.
Health Catalyst, Inc. sale notice lists 4,471 shares of common stock proposed to be sold through Morgan Stanley Smith Barney LLC.
The filing shows 9,762 shares of restricted stock were sold in the past three months and that shares outstanding were 70,730,884 as of 02/26/2026. The securities are identified as restricted stock issued for compensation.
Health Catalyst, Inc. filing a Form 144 discloses a proposed sale of 7,522 restricted shares of common stock on 02/26/2026 under a compensation-related plan. The excerpt also shows a prior sale on 12/01/2025 of 20,619 restricted shares by the same reporting address.
Health Catalyst, Inc. filing notifies a proposed sale of 28,875 restricted common shares to be sold on 02/26/2026. The sale is listed as compensation stock and identifies Morgan Stanley Smith Barney LLC at 1 New York Plaza as the broker.
The filing names Daniel Burton and shows prior restricted stock sales of 55,715 shares on 12/01/2025 for $161,584.64. Shares outstanding are listed as 70,730,884 as of 02/26/2026.
Health Catalyst, Inc. reported that director Duncan Gallagher received a grant of 7,562 shares of common stock in the form of restricted stock units under the company’s 2019 Stock Option and Incentive Plan. Following this award, his directly held common stock holdings total 132,023 shares. According to the award terms and the non-employee director compensation policy, 100% of these RSUs vested on February 17, 2026, meaning each unit has already converted into one share of common stock, subject to the plan’s conditions.
Health Catalyst, Inc. received an updated ownership disclosure from investment firm Whetstone Capital Advisors, LLC and its manager David Atterbury. They report beneficial ownership of 5,782,941 shares of common stock, equal to 8.2% of the company based on 70,730,884 shares outstanding as of November 5, 2025.
The position includes 1,515,000 shares underlying long options, purchased for an aggregate of about $17.7 million using fund capital. Whetstone and Atterbury share voting and disposition power over all reported shares. They also hold 15,150 long options exercisable for 1,515,000 shares and have sold short 30,300 option contracts tied to Health Catalyst stock, all exercisable until December 18, 2026.
Health Catalyst, Inc. named Ben Albert as its new Chief Executive Officer and a director, effective February 12, 2026, as part of an accelerated succession plan for retiring CEO Dan Burton, who will move to a strategic advisor role under an expected transition agreement.
Albert, previously President and COO and former CEO/co‑founder of Upfront Healthcare, will receive a $600,000 base salary, an annual bonus target equal to 100% of salary, 465,000 RSUs, and 465,000 performance-based RSUs, along with amended vesting of 467,000 RSUs granted in 2025. The company is also reshaping governance: multiple long‑tenured directors are resigning and the Board will ultimately be reduced to five members immediately prior to the 2026 annual meeting, with Justin Spencer serving as chair and committee memberships rebalanced.
Health Catalyst, Inc. announced a leadership transition in its commercial organization. The Board of Directors determined that Kevin Freeman will cease serving as Chief Commercial Officer on February 1, 2026. The company and Mr. Freeman anticipate entering into a separation agreement and then an independent contractor agreement under which he will serve as a senior advisor starting February 2, 2026.
The separation agreement is expected to provide Mr. Freeman with separation benefits under the company’s Executive Severance Plan, in exchange for a general release of claims. The plan was previously described in the company’s definitive proxy statement filed on May 19, 2025. The filing also notes that statements about the anticipated agreements are forward-looking and subject to risks and uncertainties.
Whetstone Capital Advisors and David Atterbury have filed a Schedule 13D on Health Catalyst, Inc. They report beneficial ownership of 5,265,377 shares of common stock, or 7.4% of the company, including 1,515,000 shares issuable upon exercise of long call options. The stake was acquired for approximately $15,701,426 of fund capital.
The filing describes an active investment approach. On January 15, 2026, the reporting persons notified Health Catalyst that they intend to submit a shareholder proposal aimed at improving corporate governance at the next annual or special meeting. Proposed changes include immediate declassification of the board, majority voting standards to amend the charter and bylaws, shareholder rights to call special meetings and act by written consent, separation of the CEO and board chair roles, and term limits for directors and members of the nominating and governance committee.
The investors indicate they may continue discussions with management, the board, and other shareholders, and could increase or decrease their position or use derivatives depending on company performance, market conditions, and other investments.